For decades, Kao Corporation has reigned as Japan's undisputed champion of Fast-Moving Consumer Goods (FMCG) and cosmetics. From laundry detergents to premium skincare, the brand has historically enjoyed immense popularity in the Chinese market, revered as the ultimate symbol of Japanese quality and safety.
During the mid-2010s inbound tourism boom, the explosive sales of Kao's "Merries" baby diapers became a social phenomenon. Wealthy and middle-class Chinese parents bought them in such massive quantities—both through cross-border e-commerce and physical "daigou" (surrogate shopping) in Japan—that the product frequently vanished from Japanese drugstore shelves. Similarly, Kao's sensitive-skin cosmetics lines, such as "Curél" and "freeplus," established a rock-solid position among Chinese millennials.
Fast forward to 2026, and Kao's China operations are weathering an unprecedented storm. The "Merries Miracle" has collapsed under the dual weight of highly advanced local Chinese brands and a severe demographic shift. Furthermore, its cosmetics division hit a massive roadblock triggered by the 2023 Fukushima ALPS-treated water release, which severely damaged consumer sentiment toward Japanese beauty brands (J-Beauty).
This report dissects the structural challenges fueling Kao's current struggles—specifically, the rise of agile C-Beauty (Chinese Beauty) and the perilous "Masstige Trap"—and explores the painful yet necessary survival strategies the giant is undertaking to rebuild its empire in the world's most competitive consumer market.
1. The Glory Days: The "Merries" Miracle
Kao's footprint in China began in 1993 with a joint venture in Shanghai. While it initially struggled to build distribution networks for its basic toiletries across the vast country, the turning point arrived with the digital and cross-border e-commerce explosion of the 2010s.
Kao's China Trajectory
Established a joint venture in Shanghai, introducing shampoo and detergents.
"Merries" baby diapers become a massive hit among Chinese consumers seeking safe, high-quality "Made in Japan" products, driving record profits for the entire Kao group.
The "Dual Shock": A plummeting Chinese birthrate and the rise of hyper-competitive local brands decimate diaper sales. The 2023 ALPS treated water release severely impacts cosmetics sales.
Massive structural reforms initiated, including the discontinuation of unprofitable mass-market brands and a pivot to high-value dermatological science.
The "Merries" boom was largely driven by a profound lack of trust in domestic Chinese products at the time. Following several domestic safety scandals, Chinese parents under the one-child policy were willing to pay extreme premiums for the absolute safety and superior breathability guaranteed by the "Made in Japan" label.
2. Data Analysis 1: The Collapse of the Diaper Empire
However, the "Merries Myth" began to crumble rapidly as the 2020s approached, struck by two insurmountable macroeconomic waves.
Figure 1: Estimated Market Share of Baby Diapers in China (Japanese Brands vs. Local Chinese Brands) — Source: Industry estimates
The Two Waves Destroying Foreign Diaper Dominance
- The Evolution of Local Brands (e.g., Babycare):
The era of "cheap and inferior" Chinese goods is long gone. Local manufacturers now source the best materials globally to create diapers that match or exceed foreign brands in functionality. Brands like "Babycare" captured Gen Z parents with superior design aesthetics and aggressive livestream marketing, rapidly stealing market share. - The Demographic Collapse:
China's annual births plummeted from a peak of 18.8 million in 2016 to around 9 million by 2023. As the overall pie shrank drastically, high-priced imported goods were the first to be squeezed out of the market.
3. Data Analysis 2: The "Masstige Trap" in Cosmetics
As diapers faltered, Kao relied heavily on its cosmetics division. Brands like "Curél" (targeting dry, sensitive skin) and "freeplus" were highly favored by young Chinese consumers. Yet, a severe structural weakness lay hidden in Kao's portfolio positioning.
Figure 2: Competitive Positioning in China's Cosmetics Market by Price Tier (Estimates) — *Kao is heavily concentrated in the mid-tier, facing the full force of top C-Beauty brands.
As shown in Figure 2, the Chinese cosmetics market is segmented into three primary tiers:
- Prestige (High-End): Dominated by global giants like L'Oréal, Estée Lauder, and Shiseido (Clé de Peau Beauté). This tier remains somewhat insulated from local competition.
- Masstige (Mid-Tier): This is Kao's primary battlefield (Curél, freeplus). Unfortunately, it is also the exact tier where top C-Beauty brands like Proya and Winona are pouring all their resources, creating a hyper-competitive "Red Ocean."
- Mass (Low-End): Dominated by emerging, ultra-cheap domestic brands.
While rivals like Shiseido successfully pivoted their China operations toward ultra-premium "Prestige" brands, Kao was slow to introduce its top-tier lines (like SENSAI). Consequently, Kao found itself stuck in the "Masstige Trap"—forced into a bloody price war against well-funded, technologically advanced Chinese brands offering similar functional benefits at lower prices (known in China as Pingti, or affordable alternatives).
4. The Geopolitical Shock and the "Agility Deficit"
The final blow to Kao's mid-tier dominance was the geopolitical fallout from the summer of 2023. The release of ALPS-treated water from the Fukushima nuclear plant triggered widespread nationalistic backlash on Chinese social media (Douyin, RED), with influencers questioning the safety of Japanese cosmetics.
While ultra-wealthy consumers buying Prestige brands remained relatively loyal, the middle-class and Gen Z consumers in the Masstige tier—Kao's core demographic—were highly sensitive to this social media narrative, accelerating a massive shift toward domestic C-Beauty brands.
Figure 3: Kao's Consumer Products Revenue Trend in Asia/China (Index: 2018=100) — Source: Company filings and projections
Beyond geopolitics, Kao's most fundamental flaw was its "Agility Deficit." The modern Chinese market operates on a C2M (Consumer-to-Manufacturer) model. Local brands scrape real-time data from Douyin livestreams, identify a niche skin issue, and launch a targeted product in mere months. Conversely, traditional Japanese giants like Kao—bound by strict, prolonged R&D cycles in Japan—take over a year to export a product. By the time a Japanese product reaches Chinese shelves, the local trend has already moved on.
5. The 2026 Turnaround: Retreating to "Hardcore Science"
Driven by a profound sense of crisis, Kao's executive team is currently executing a painful but necessary restructuring of its China portfolio. The strategy is clear: ruthlessly cut unprofitable mass-market brands and consolidate resources into areas where local competitors cannot easily follow.
Breaking Through with Irreplaceable Dermatological Evidence
Kao's ultimate weapon to reclaim the Chinese market isn't flashy influencer marketing, but a return to its 130-year legacy of hardcore foundational research (Science).
Take its flagship brand "Curél." Kao possesses arguably the world's most advanced proprietary "Ceramide functioning ingredient" technology. Instead of relying on vague marketing terms like "gentle on skin," Kao is pivoting to hard clinical evidence. By partnering with leading Chinese dermatologists and "ingredient-geek" influencers, Kao is scientifically demonstrating why its ceramides repair the skin barrier better than local alternatives.
True "In China, For China" R&D
Furthermore, Kao is decentralizing its R&D. Moving away from the outdated "Made in Japan, Sold in China" model, the company is drastically expanding its Shanghai R&D centers to achieve a true "In China, For China" agile development cycle, tailored specifically to the unique environmental stressors (pollution, climate) faced by Chinese consumers.
6. Conclusion: The Real Test of Value Creation
The magic words "Made in Japan" have lost their spell. The dramatic rise and subsequent struggles of Kao's diaper and cosmetics businesses in China perfectly encapsulate the brutal reality facing all foreign FMCG multinationals today: Legacy brand equity and basic quality are no longer sufficient to justify a price premium against China's hyper-agile, tech-driven domestic manufacturers.
As we move through 2026, Kao's China operations have entered a qualitative transformation phase. The company must escape the bloody "Masstige Trap" not by cutting prices, but by leveraging its unparalleled interface and dermatological science to create "sharp, irreplaceable functional value" that Chinese consumers are willing to pay a premium for. The true resilience of Japan's FMCG giant is being tested right now on the front lines of the world's toughest consumer market.